An experimental COVID-19 treatment pill developed by Merck is significantly less effective than earlier data suggested.
The U.S. drugmaker said its oral pill showed a 30 percent reduction in deaths and hospitalizations based on its updated analysis while its previous data claimed a 50 percent reduction.
Merck released the data before the U.S. Food and Drug Administration published a set of documents on Friday.
And, the FDA's committee comprised of outside experts will meet on Tuesday to discuss whether to authorize the pill.
Merck's shares dropped by almost 3.8 percent on Friday.